Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Busulfan-induced hepatitis.

L E Morris1, T H Guthrie

  • 1Medical College of Georgia, Augusta.

The American Journal of Gastroenterology
|June 1, 1988
PubMed
Summary
This summary is machine-generated.

Busulfan, a chemotherapy drug, can cause liver damage (hepatitis) in patients with chronic myelocytic leukemia. Discontinuing busulfan treatment led to the resolution of liver enzyme abnormalities and fever in one patient.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel approach to 3D modelling ground-penetrating radar (GPR) data - A case study of a cemetery and applications for criminal investigation.

Forensic science international·2021
Same author

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.

Leukemia·2017
Same author

Telemedicine in the UK Defence Medical Services: time for an upgrade?

Journal of the Royal Army Medical Corps·2016
Same author

Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation.

Bone marrow transplantation·2016
Same author

Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning.

Bone marrow transplantation·2015
Same author

Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.

Bone marrow transplantation·2014
Same journal

Calendar of Courses, Symposiums and Conferences.

The American journal of gastroenterology·2026
Same journal

Molecular Nonendoscopic Tests for the Early Detection of Esophageal Squamous Carcinoma and High-Grade Dysplasia: Promising Progress.

The American journal of gastroenterology·2026
Same journal

ACG Clinical Guideline: Colonic Diverticulitis.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: July 2026.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: July 2026.

The American journal of gastroenterology·2026
Same journal

2026 CME Information.

The American journal of gastroenterology·2026
See all related articles

Area of Science:

  • Hepatology
  • Oncology
  • Pharmacology

Background:

  • Chronic myelocytic leukemia (CML) is a myeloproliferative neoplasm.
  • Busulfan is an alkylating agent used in the treatment of CML.
  • Long-term busulfan therapy can be associated with various toxicities.

Observation:

  • A 61-year-old male CML patient on long-term busulfan therapy presented with cholestatic liver enzyme elevation, fever, and abdominal pain.
  • Imaging studies (ultrasound, CT scan) revealed no structural abnormalities in the liver or biliary tract.
  • Percutaneous liver biopsy showed cellular cholestasis and focal hepatocellular necrosis with inflammation.

Findings:

  • The clinical presentation and liver biopsy findings were consistent with drug-induced liver injury.

Related Experiment Videos

  • Discontinuation of busulfan resulted in normalization of liver enzymes and resolution of symptoms.
  • The case suggests busulfan as the causative agent for hepatitis.

    • Implications:

    • Busulfan-induced hepatitis is a potential, albeit rare, complication of long-term CML treatment.
    • Clinicians should consider drug-induced liver injury in patients on busulfan presenting with cholestatic jaundice.
    • Monitoring liver function is crucial in patients undergoing long-term busulfan therapy.